INTRODUCTION AND OBJECTIVES: While 68Ga-prostatespecific membrane antigen (PSMA) positron emission tomography (PET) is being used for restaging patients with suspected biochemical recurrence (BCR) of prostate cancer, the use of 18F-labeled PSMA ligands is increasing owing to their longer half-life, ease of larger batch production and lower positron range compared with 68Ga-labelled counterparts. Radiohybrid PSMA (rhPSMA) ligands are a new class of theranostic PSMA-targeting agents featuring fast 18F synthesis with utility for labeling with radiometals. This retrospective analysis evaluated the efficacy of 18F-rhPSMA7 PET/CT for imaging BCR of prostate cancer.
METHODS: Datasets from 261 consecutive patients with noncastrate BCR after radical prostatectomy who underwent 18F-rhPSMA7 PET/CT between June 2017 and March 2018 were retrospectively reviewed by a nuclear medicine physician. All suspicious lesions were documented and detection rates were correlated with patients 0 PSA level, primary Gleason score, and prior therapy (androgen deprivation therapy [ADT] and external beam radiation therapy [EBRT]).
RESULTS: The 261 patients had a median PSA level of 0.96 (range, 0.01 -400) ng/mL. The median injected activity of 18F-rhPSMA7 was 336 MBq, with a median uptake time of 76 (range, 50 -220) min.
18F-rhPSMA7-avid lesions were found in 211/261 (80.8%) patients. Among those with PSA < 0.2 ng/mL, 7/22 (31.8%) had suspicious lesions. The detection rate was broadly proportional to PSA; 71.2% (42/59), 86.3% (44/51), 85.7% (42/49) and 95.0% (76/80) at PSA levels of 0.2 -< 0.5, 0.5 -< 1 , 1 -< 2 and ! 2 ng/mL, respectively.
18F-rhPSMA7 revealed local recurrence in 113 (43.3%) patients. Pelvic lymph node metastases were present in 110 (42.2%), while lymph node metastases were found in retroperitoneal and supradiaphragmatic regions in 45 (17.2%) and 21 (8.0%) patients, respectively. Bone and visceral metastases were detected in 54 (20.7%) and 10 (3.8%) patients, respectively.
Detection rates were not influenced by patients 0 prior therapy (79.1% among those with prior EBRT vs. 82.1% without prior EBRT, p [ 0.55); by ADT in the 6 months preceding imaging (80.6% among patients receiving ADT vs. 80.9% in those not prescribed ADT, p [ 0.54); or by primary Gleason score (77.9% among patients with Gleason score 7 vs. 82.6% for scores !8, p [ 0.38).
INTRODUCTION AND OBJECTIVES: Presently, prostate biopsy (PBx) results report the highest Gleason Grade Group (GGG) as a metric to gauge the overall aggressiveness of cancer and dictate treatment. Intuitively, we presumed a PBx showing multiple cores of cancer with more volume cancer per core would represent more aggressive disease. We previously proposed the Weighted Gleason Grade Group (WGGG), a novel scoring system that synthesizes all histopathologic data and cancer volume into a single numeric value representing the entire PBx, to more accurately predict adverse pathologic outcomes of radical prostatectomy (RP). This work is now extended to a second database at another institution to assess this latter potential.
METHODS: We studied 171 men who underwent RP after standard multi-core PBx at a single academic institution. WGGG was calculated by summing the values of each positive core described by the formula: GGG þ (GGG x % Ca/core), and normalized for a 12-core total, for a possible value ranging from 1 to 120. RP pathology was assessed for extraprostatic extension (EPE), seminal vesical invasion (SVI), lymph node involvement (LNI), and positive surgical margins (PSM). We compared GGG vs WGGG receiver operating characteristic (ROC) areas under the curve (AUC) for each adverse feature. We then used a second group of 389 men from another academic institution to confirm the discriminatory advantage of WGGG.
RESULTS: Baseline characteristics for both cohorts are listed in the Table. For the development group, the AUCs for the WGGG vs. GGG were significantly higher for predicting EPE (0. CONCLUSIONS: The WGGG, by providing a metric reflecting the entirety of the PBx, is more informative than conventional single GGG alone in predicting adverse pathologic outcomes on RP specimens. This superior discriminatory capability has been achieved without any consideration of other available clinical disease characteristics and should help the urologist to better evaluate his patient candidates for RP.
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MP09-18 MODIFIED INJECTION TECHNIQUE IN SENTINEL LYMPH NODE DETECTION IN PROSTATE CANCER: TARGETING THE INDEX LESION
Lluís Fumad o*, Antoni Mestre-Fusco, Jose María Abascal, Marc Costa, Nuria Juanpere, Josep Lloreta-Trull, Segri Vidal-Sicart, Lluís Cecchini, Barcelona, Spain INTRODUCTION AND OBJECTIVES: Extended pelvic lymphadenectomy (ePLND) is the best staging procedure for lymph node involvement in pacients with prostate cancer, with controversial evidence regarding oncological benefits. In this setting, Sentinel lymph node biopsy may play a role in tailoring the surgery, but the best way to perform it is still controversial. We explored how useful could be to inject 99mTc-nanocolloid only to the index lesion.
METHODS: A prospective study has been performed between June 2016 and September 2018. It involved 33 patients (median age 67 year-old) diagnosed with localised intermediate or high-risk prostate cancer with >5% in MSKCC nomogram for lymph node involvement. Those patients all had an MRI with an index lesion, and pathologically comfirmed.
The day before surgery a radiotracer (240-30 MBq in 0.6 cc volume) was injected only to the index lesion and its peripheral area through cognitive-fusion technique guided by transrectal ultrasound (2-4 injections). A lymphoscintigraphy was subsequently performed with planar images taken at 30 minuts and 3-4 hours post-injection.
The surgical procedure included the laparoscopic radical prostatectomy (LP) with sentinel lymph node (SLN) biopsy and ePLND. SLN was intraoperatively detected by a gamma probe.
RESULTS: All patients were cT1-T3 N0, ISUP grade 2-5. The final pathology demonstrated 11(33.3 %) pT2, 17(51.5%) pT3a, and 5(15.2%) pT3b, with 24(72.7%) pN0 and 9(27.3%) pN1.
Lymph node dissection included 16.3 lymph nodes per patient , with 3.3 SLN (IQR 2-4.5). Mean surgical time for LP þ SLN þ ePLND was 208 min (IQR 180-240) with 3% transfusion rate (1/33).
SLN biopsy was positive in 9 patients (27.3%). None of pathologically negative SLN resulted in a pN1; this represents a PPV and NPV of 100%. Sensitivity and specificity were also 100%. FN was 0% and FP 6% (two cases with SLNs containing metastases outside the ePLND template while the ePLND template did not reveal any metastases). Diagnostic yield was 94% and non diagnostic rate 6%.
At a lesion level, a total of 543 lymph nodes were harvested, 104(19.1%) were SLN, 10(9.6%) outside the ePLND area. In total, 22(4%) were positive, 14 within the SLNs and 8 in the ePLND, leading in a 63.6% of metastasis in SN only.
CONCLUSIONS: Radiotracer injection to the prostate index lesion offers promising results and an excellent results for staging in those cases where sentinel lymph node dissection is considered. Negative SLN is a predictor of negative ePLND.
